The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Adjunctive gabapentin treatment of bipolar disorder
Abstract
Introduction: The aim of this study was to analyze the effectiveness of gabapentin administration to bipolar patients who had an incomplete response to other mood stabilizers. Subjects and methods: Twenty-two RDC bipolar 1 and II patients were assessed by means of the SADS and entered if they gave their consent to participate. All them had suffered from frequent relapses, subsyndromal features (mostly depressive) and incomplete response to other drugs. They all received open-label increasing doses of gabapentin until clinical response. The patients were assessed through the CGI-BP and a specific questionnaire at baseline and at 12 weeks of follow-up. Results: Six out of the 22 patients dropped out for various reasons (four because of relapse, one because of side effects and one more because of poor compliance). Eight of the 16 patients that completed the 12-week follow-up showed at least two stages of improvement in the CGI. Using the last observation-carried forward analysis, the improvement was statistically significant for the depression subscale, and apparently related to social functioning, irritability and anxiety. Only one patient dropped out because of intolerance (mild rash). The mean dose of gabapentin was 1,310 mg/day. Conclusion: Gabapentin may be a useful drug for the add-on treatment of bipolar patients with poor response to other mood stabilizers. Gabapentin may improve depressive residual symptoms such as irritability, social withdrawal or anxiety. These results should be confirmed in randomized clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gabapentin employed as an adjunctive therapy in open‐label studies reduced anxiety symptoms in patients with BD (level 4).696, 729”
Citations
Cites
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Treatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395
Dichter, M. A., & Brodie, M. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342407 · Cited by 340
Mood Stabilizer Combinations: A Review of Safety and Efficacy
Freeman, M. P., & Stoll, A. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.12 · Cited by 204
Anxious and non-anxious bipolar disorder
Trevor Young, L., Cooke, R. G., Robb, J. C., Levitt, A. J., & Joffe, R. T. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90118-4 · Cited by 178
Gabapentin as a Potential Treatment for Anxiety Disorders
Pollack, M. H., Matthews, J., & Scott, E. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.992 · Cited by 158
Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications
Baldessarini, R. J., Tondo, L., & Viguera, A. C. (1999) · Bipolar Disorders · doi:10.1034/j.1399-5618.1999.10106.x · Cited by 156
Gabapentin in the treatment of bipolar disorder
Schaffer, C. B., & Schaffer, L. C. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.2.291 · Cited by 111
Anticonvulsants and antipsychotics in the treatment of bipolar disorder.
Keck, P. E., McElroy, S. L., & Strakowski, S. M. (1998) · PubMed · Cited by 101
A Pilot Trial of Adjunctive Gabapentin in the Treatment of Bipolar Disorder
McElroy, S. L., Soutullo, C. A., Keck, P. E., & Kmetz, G. F. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1026257303275 · Cited by 99
Research works printed but not linked: 2
- Pande, 1999, Combination treatment in bipolar disorder, Bipolar Disord, 1, 17
- Vieta, 1999, Anticonvulsants in psychiatry. Round table series n° 64, 3
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“In patients with bipolar disorder, adjunctive valproate and gabapentin have demonstrated efficacy for the treatment of panic disorder [281,1414] and resulted in reductions in anxiety symptoms [1415,1416].”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“Several open studies suggest antidepressant properties of adjunctive gabapentin (Young et al. 1997; Altshuler et al. 1999; Vieta et al. 2000; Yasmin et al. 2001), but the methodologically best study for gabapentin to date could not fi nd a separation from placebo in treatment-resistant unipolar or bipolar depression.”
BackgroundSelf-citationYatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
“Open-label adjunctive gabapentin has been shown to improve residual depressive symptoms, irritability, social withdrawal and anxiety in patients with refractory bipolar disorder (level 3) (172, 569).”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“Finally, another open-label study which enrolled BD-I or -II patients with subsyndromal features (YMRS> 6 or HAM-D> 12, and CGI-B>3) found again that, while mania scores did not substantially improve, depression was significantly improved (P< 0.002) (Vieta et al. 2000).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Vieta, E., Martinez-Arán, A., Nieto, E., Colom, F., Reinares, M., Benabarre, A., & Gastó, C.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Corresponding author
- Vieta, E
- Venue
- European Psychiatry
- Publisher
- Cambridge University Press (CUP)
- Published
- 2000-11
- Volume
- 15
- Issue
- 7
- Pages
- 433-437
- ISSN
- 0924-9338 (ISSN-L)
- 1778-3585
- OpenAlex
- W2057301133
- Cited by
- 46
- References
- 20
- Citations by year
- 2024: 2 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 2 · 2012: 4
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- gabapentin, bipolar disorder, adjunctive therapy, mood stabilizers, relapse, depressive symptoms, irritability, social functioning, anxiety
- MeSH terms
- Gabapentin, Acetates, Adult, Amines, Anticonvulsants, Bipolar Disorder, Cyclohexanecarboxylic Acids, Drug Therapy, Combination, Female, Follow-Up Studies, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Treatment Outcome, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive gabapentin treatment of bipolar disorder. https://app.cochat.ai/papers/10.1016/s0924-9338(00)00514-9
- The paper
- Vieta, E., Martinez-Arán, A., Nieto, E., Colom, F., Reinares, M., Benabarre, A., & Gastó, C. (2000). Adjunctive gabapentin treatment of bipolar disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(00)00514-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.